Cidara Therapeutics, Inc. (CDTX) financial statements (2020 and earlier)

Company profile

Business Address 6310 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments507575105108
Cash and cash equivalents5075618563
Short-term investments  151945
Restricted cash and investments10    
Receivables  0  
Other undisclosed current assets63211
Total current assets:667778105108
Noncurrent Assets
Operating lease, right-of-use asset2
Property, plant and equipment01112
Other noncurrent assets11000
Total noncurrent assets:32122
TOTAL ASSETS:697979107110
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1010996
Accounts payable23333
Accrued liabilities44431
Employee-related liabilities43331
Debt11103  
Derivative instruments and hedges, liabilities 0   
Other undisclosed current liabilities10    
Total current liabilities:30201296
Noncurrent Liabilities
Long-term debt and lease obligation1    
Operating lease, liability1
Liabilities, other than long-term debt 0 00
Other liabilities 0 00
Other undisclosed noncurrent liabilities  710 
Total noncurrent liabilities:107100
Total liabilities:312019196
Stockholders' equity
Stockholders' equity attributable to parent38596088104
Common stock00000
Additional paid in capital298278209182149
Accumulated other comprehensive loss  (0)(0)(0)
Accumulated deficit(260)(219)(149)(94)(45)
Total stockholders' equity:38596088104
TOTAL LIABILITIES AND EQUITY:697979107110

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(63)(63)(56)(48)(32)
Other undisclosed operating income21    
Operating loss:(42)(63)(56)(48)(32)
Nonoperating income (expense)14(0)00
Other nonoperating income (expense)14(0)0 
Interest and debt expense(0)(0)(0)(0)(0)
Net loss:(41)(59)(56)(48)(32)
Other undisclosed net income attributable to parent00000
Net loss attributable to parent:(41)(59)(56)(48)(32)
Preferred stock dividends and other adjustments (10)   
Net loss available to common stockholders, diluted:(41)(69)(56)(48)(32)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(41)(59)(56)(48)(32)
Comprehensive loss:(41)(59)(56)(48)(32)
Other undisclosed comprehensive income, net of tax, attributable to parent00000
Comprehensive loss, net of tax, attributable to parent:(41)(59)(56)(48)(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: